4.000USD-2.44%Mkt Cap: 16.61M USDP/E: —Last update: 2026-05-26
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap16.61M USD
Enterprise Value16.55M USD
Revenue (TTM)209.03K USD
Gross Profit48.95K USD
Net Income (TTM)-13.38M USD
Revenue/Share0.0560 USD
Last Price4.000 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS98978N2009
Valuation
P/E (Trailing)—
P/E (Forward)-3.38
PEG—
EV/EBITDA—
EV/Revenue79.18
P/S80.64
P/B-4.73
EPS (TTM)-2.18
EPS (Forward)-1.20
52W Range
1.11016% of range19.65
52W High19.65 USD
52W Low1.110 USD
Profitability
Gross Margin31.14%
Oper. Margin-1551.76%
EBITDA Margin0.00%
Profit Margin-8513.44%
ROE2599.52%
ROA-814.60%
Growth
Revenue Growth108.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.31M USD
CapEx (TTM)—
FCF Margin-1252.12%
FCF Yield-15.76%
Net Debt762.47K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.49
Current Ratio0.08
Quick Ratio0.02
Book Value/Sh-0.8580 USD
Cash/Share0.0150 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateOct 27, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.15M
Float1.94M
Insiders47.46%
Institutions0.11%
Short Interest
Short Ratio6.7d
Short % Float2.61%
Short % Out.2.04%
Shares Short35.47K
Short (prev mo.)12.81K
Technical
SMA 504.545 (-12.0%)
SMA 20010.04 (-60.2%)
Beta0.06
S&P 52W Chg28.31%
Avg Vol (30d)5.10K
Avg Vol (10d)1.71K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—